IONS Short Information, Ionis Pharmaceuticals Inc.

Twenty Trading Day Totals
Total Shorted Volume	1,937,581
Total Actual Volume	18,962,744

Averages
Average Short Volume	96,879
Average Short Percentage	37.51%

Is there a IONS Short Squeeze or Breakout about to happen?

See the IONS Short Analysis for free Sign up or Login

Stock Date	Open Price	Close Price	High	Low	Total Volume	Short Volume	Short Percentage
2022-06-30	37	37.02	37.76	36.68	774,263	58,502	25.0421
2022-06-29	37.9	37.56	38.37	37.24	754,235	34,027	14.8181
2022-06-28	39.64	37.97	39.83	37.81	718,746	32,321	17.6999
2022-06-27	39.33	39.34	39.61	38.53	821,312	89,723	48.0589
2022-06-24	39.27	39.25	39.51	37.64	1,474,934	93,191	25.6659
2022-06-23	37.64	39.02	39.15	37.44	918,699	70,703	30.4708
2022-06-22	36.84	37.24	37.96	36.646	937,702	71,011	39.2332
2022-06-21	36.01	37.41	38.15	35.97	1,246,493	156,538	56.5607
2022-06-16	34.1	33.73	34.64	33.21	704,006	76,322	53.7596
2022-06-15	33.82	34.67	35.18	33.82	620,908	45,880	32.9602
2022-06-14	33.71	33.51	33.77	32.805	984,148	173,657	73.0216
2022-06-13	34.08	33.5	34.125	32.965	1,262,106	158,944	61.0225
2022-06-09	34.7	34.93	35.425	34.41	1,032,633	301,241	65.0035
2022-06-08	35.03	35	35.69	34.74	951,987	160,630	41.2343
2022-06-06	36.35	34.02	36.76	33.76	859,735	92,991	43.2060
2022-06-03	35.78	36.15	36.58	35.05	749,760	48,322	26.9744
2022-06-02	35.89	35.86	36.06	35.02	677,882	39,307	29.3391
2022-06-01	36.69	35.91	36.83	35.53	854,372	31,621	24.0760
2022-05-31	37.74	36.52	37.99	36.07	999,552	39,945	19.2886
2022-05-26	37.17	36.65	37.85	36.56	1,619,271	162,705	22.7527

Stock Information

Ionis Pharmaceuticals Inc. Company Name:

IONS Stock Symbol:

NASDAQ Market:

IONS Short Information, Ionis Pharmaceuticals Inc.

Get IONS Alerts

News, Short Squeeze, Breakout and More Instantly...

IONS - Ionis announces presentation of positive Phase 2b data for chronic hepatitis B treatment at the EASL International Liver Congress(TM)

Ionis announces presentation of positive Phase 2b data for chronic hepatitis B treatment at the EASL International Liver Congress™ PR Newswire - Interim analysis of B-Clear clinical study of bepirovirsen demonstrated end-of-treatment virologic response (VR) in p...
IONS - Ionis announces eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)

Ionis announces eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) PR Newswire - Eplontersen showed statistically significant and clinicall...
IONS - Ionis treatment for Angelman syndrome receives orphan drug and rare pediatric disease designations from U.S. FDA

Ionis treatment for Angelman syndrome receives orphan drug and rare pediatric disease designations from U.S. FDA PR Newswire CARLSBAD, Calif. , June 13, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeuti...